Nabriva Therapeutics (NBRVF) 10-Q2018 Q1 Quarterly report

Filed: 8 May 18, 8:01am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: adapt, affiliate, aggressive, allotment, analyze, ancillary, anniversary, ATM, bid, bidding, bill, bipartisan, bulk, Cadillac, Century, chain, chamber, China, Chinese, companion, concert, CSR, CTA, cure, de, deliverable, device, disapplication, disapply, discourage, donut, entirety, EU, excise, fifty, frustrate, frustrating, frustration, highest, hole, Hong, hostile, imminent, inclusion, incremental, indirect, JDC, Kong, Macau, mandate, milestone, modernize, move, neutrality, nil, OfferingSM, official, organizational, overhead, Panel, partly, People, preemption, redemption, Republic, residual, rest, Roivant, routine, royalty, RSU, rulemaking, serialization, Sinovant, skinny, solvent, spur, Taiwan, takeover, Territory, tied, tribunal, unclear, uncured, undermine, unissued, unwanted, upfront, variable, wind, winding

Removed: accretive, acting, actively, actuarial, actuary, acute, Affordability, age, agent, allocation, amounted, applied, auditing, bargaining, brand, calculated, CardConnect, Cempra, Center, chemical, CMS, commencing, condensed, Continental, CONTRA, deal, deferral, depart, depending, desire, determinable, diversion, domestic, dose, eliminating, energy, entail, episode, examination, expanded, expensed, explore, facility, frame, furniture, HABP, healthy, HIPPA, implanted, ineffectively, influenza, infused, inhaled, injected, innovative, insider, instilled, integration, intent, IPAB, jubilee, King, landlord, Leberstrasse, letter, Liegenschaftsverwaltung, lowering, mailing, managed, men, method, methodology, moderate, momentum, noncurrent, November, opening, outpatient, PA, potent, prepare, principle, printing, prosthetic, Prussia, realization, recommend, redomiciled, relate, relocation, rental, repealing, replacing, response, retention, retirement, salary, Select, selected, selective, sexually, short, simplification, skin, solicitation, solithromycin, statistical, statistically, Suite, taxing, test, topical, training, transmitted, turn, twelve, underwritten, undiscounted, unit, unlimited, USA, VABP, Vienna, voted, waiver, Wiener, women, WWFF

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NBRVF similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Nabriva Therapeutics plc (the “Company”) for the period ended March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Gary Sender, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Gary Sender

Gary Sender
Chief Financial Officer
(Principal Financial Officer)

Dated: May 8, 2018